Arbutus Biopharma (ABUS) Financials

$3.29 -0.05 (-1.50%)

Closing price 04:00 PM Eastern

Extended Trading

$3.32 +0.03 (+0.91%)

As of 07:13 PM Eastern

Annual Income Statements for Arbutus Biopharma

This table shows Arbutus Biopharma's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2022	2023	2024
Net Income / (Loss) Attributable to Common Shareholders	-69	-73	-70
Consolidated Net Income / (Loss)	-69	-73	-70
Net Income / (Loss) Continuing Operations	-69	-73	-70
Total Pre-Tax Income	-65	-73	-70
Total Operating Income	-65	-78	-76
Total Gross Profit	39	18	6.17
Total Revenue	39	18	6.17
Operating Revenue	39	18	6.17
Total Cost of Revenue	0.00	0.00	0.00
Total Operating Expenses	104	96	82
Selling, General & Admin Expense	18	22	22
Research & Development Expense	84	74	54
Restructuring Charge	-	0.00	3.72
Other Special Charges / (Income)	2.23	0.07	2.63
Total Other Income / (Expense), net	0.44	5.25	6.40
Interest Expense	1.73	0.46	0.14
Interest & Investment Income	2.19	5.69	6.59
Other Income / (Expense), net	-0.02	0.03	-0.05
Income Tax Expense	4.44	0.00	0.00
Basic Earnings per Share	($0.46)	($0.44)	($0.38)
Weighted Average Basic Shares Outstanding	150.94M	165.96M	185.61M
Diluted Earnings per Share	($0.46)	($0.44)	($0.38)
Weighted Average Diluted Shares Outstanding	150.94M	165.96M	185.61M
Weighted Average Basic & Diluted Shares Outstanding	162.57M	179.49M	191.48M

This table shows Arbutus Biopharma's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Net Income / (Loss) Attributable to Common Shareholders	-18	-22	-16	-17	-20	-19	-18	-20	-20	-13
Consolidated Net Income / (Loss)	-18	-22	-16	-17	-20	-19	-18	-20	-20	-13
Net Income / (Loss) Continuing Operations	-18	-22	-16	-17	-20	-19	-18	-20	-20	-13
Total Pre-Tax Income	-18	-22	-16	-17	-20	-19	-18	-20	-20	-13
Total Operating Income	-18	-23	-17	-18	-22	-21	-19	-22	-21	-14
Total Gross Profit	5.95	6.25	6.69	4.65	4.66	2.15	1.53	1.73	1.34	1.57
Total Revenue	5.95	6.25	6.69	4.65	4.66	2.15	1.53	1.73	1.34	1.57
Operating Revenue	5.95	6.25	6.69	4.65	4.66	2.15	1.53	1.73	1.34	1.57
Total Operating Expenses	24	29	24	24	26	22	21	23	23	16
Selling, General & Admin Expense	3.49	4.25	5.55	5.98	5.84	5.10	5.31	7.55	4.54	4.71
Research & Development Expense	20	23	18	18	20	18	15	16	14	8.81
Total Other Income / (Expense), net	0.24	0.63	1.07	1.93	1.45	0.80	1.49	1.79	1.72	1.40
Interest Expense	0.43	0.31	0.20	0.17	0.05	0.04	0.04	0.03	0.03	0.03
Interest & Investment Income	0.69	0.94	1.27	1.46	1.49	1.47	1.55	1.83	1.75	1.46
Other Income / (Expense), net	-0.02	-0.00	0.00	0.64	0.01	-0.62	-0.01	-0.01	0.01	-0.03
Basic Earnings per Share	($0.12)	($0.13)	($0.10)	($0.10)	($0.12)	($0.12)	($0.10)	($0.11)	($0.10)	($0.07)
Weighted Average Basic Shares Outstanding	151.00M	150.94M	161.64M	166.06M	167.51M	165.96M	175.63M	188.04M	189.00M	185.61M
Diluted Earnings per Share	($0.12)	($0.13)	($0.10)	($0.10)	($0.12)	($0.12)	($0.10)	($0.11)	($0.10)	($0.07)
Weighted Average Diluted Shares Outstanding	151.00M	150.94M	161.64M	166.06M	167.51M	165.96M	175.63M	188.04M	189.00M	185.61M
Weighted Average Basic & Diluted Shares Outstanding	156.47M	162.57M	166.13M	167.56M	167.70M	179.49M	188.72M	188.78M	189.49M	191.48M

This table details how cash moves in and out of Arbutus Biopharma's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2022	2023	2024
Net Change in Cash & Equivalents	-79	-4.49	10
Net Cash From Operating Activities	-35	-86	-65
Net Cash From Continuing Operating Activities	-35	-86	-65
Net Income / (Loss) Continuing Operations	-69	-73	-70
Consolidated Net Income / (Loss)	-69	-73	-70
Depreciation Expense	1.43	1.40	1.38
Amortization Expense	-0.05	-2.20	-3.14
Non-Cash Adjustments To Reconcile Net Income	1.25	5.87	7.03
Changes in Operating Assets and Liabilities, net	31	-18	-0.20
Net Cash From Investing Activities	-75	51	23
Net Cash From Continuing Investing Activities	-75	51	23
Purchase of Property, Plant & Equipment	-0.51	-1.01	-0.18
Purchase of Investments	-130	-81	-142
Sale of Property, Plant & Equipment	0.00	0.02	0.00
Sale and/or Maturity of Investments	56	132	165
Net Cash From Financing Activities	32	31	52
Net Cash From Continuing Financing Activities	32	31	52
Issuance of Common Equity	21	30	45
Other Financing Activities, net	0.12	0.26	7.48
Effect of Exchange Rate Changes	-0.02	0.03	-0.05

This table details how cash moves in and out of Arbutus Biopharma's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Net Change in Cash & Equivalents	-23	6.77	9.80	-13	-9.67	8.75	17	20	-31	4.48
Net Cash From Operating Activities	-19	-17	-27	-20	-22	-17	-19	-15	-21	-10
Net Cash From Continuing Operating Activities	-19	-17	-27	-20	-22	-17	-19	-15	-21	-10
Net Income / (Loss) Continuing Operations	-18	-22	-16	-17	-20	-19	-18	-20	-20	-13
Consolidated Net Income / (Loss)	-18	-22	-16	-17	-20	-19	-18	-20	-20	-13
Depreciation Expense	0.34	0.31	0.33	0.34	0.37	0.36	0.36	0.36	0.34	0.33
Amortization Expense	-0.08	-0.22	-0.39	-0.53	-0.66	-0.62	-0.55	-0.68	-0.98	-0.92
Non-Cash Adjustments To Reconcile Net Income	-0.20	-0.26	1.15	2.37	1.79	0.57	1.46	2.64	1.78	1.15
Changes in Operating Assets and Liabilities, net	-1.19	5.12	-12	-4.64	-3.18	1.71	-2.68	2.97	-2.16	1.66
Net Cash From Investing Activities	-14	13	17	1.44	10	22	12	9.83	-12	13
Net Cash From Continuing Investing Activities	-14	13	17	1.44	10	22	12	9.83	-12	13
Purchase of Property, Plant & Equipment	-0.09	-0.13	-0.12	-0.86	-0.03	-	-0.10	-0.00	-	-0.09
Purchase of Investments	-33	-13	-20	-29	-7.09	-24	-25	-33	-40	-43
Sale and/or Maturity of Investments	19	26	37	32	18	46	37	42	28	57
Net Cash From Financing Activities	9.13	11	20	4.74	1.68	3.81	24	24	1.78	1.42
Net Cash From Continuing Financing Activities	9.13	11	20	4.74	1.68	3.81	24	24	1.78	1.42
Issuance of Common Equity	9.13	11	20	4.74	1.68	3.81	22	22	0.19	-0.00
Other Financing Activities, net	-	0.00	0.26	-	-	0.00	2.45	2.01	1.59	1.42
Effect of Exchange Rate Changes	-0.02	-0.00	0.00	-0.00	0.01	0.01	-0.01	-0.01	0.01	-0.03

This table presents Arbutus Biopharma's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2022	2023	2024
Total Assets	195	144	132
Total Current Assets	151	132	127
Cash & Equivalents	31	26	36
Short-Term Investments	116	100	86
Accounts Receivable	1.35	1.78	2.41
Prepaid Expenses	2.87	4.25	2.28
Plant, Property, & Equipment, net	5.07	4.67	3.31
Total Noncurrent Assets	39	7.70	1.08
Long-Term Investments	37	6.28	0.00
Other Noncurrent Operating Assets	1.85	1.42	1.08
Total Liabilities & Shareholders' Equity	195	144	132
Total Liabilities	59	38	34
Total Current Liabilities	33	22	16
Accounts Payable	16	10	7.56
Current Deferred Revenue	16	12	7.57
Other Current Liabilities	0.37	0.43	0.48
Total Noncurrent Liabilities	26	16	19
Noncurrent Deferred Revenue	6.00	0.00	2.86
Other Noncurrent Operating Liabilities	20	16	16
Total Equity & Noncontrolling Interests	137	106	97
Total Preferred & Common Equity	137	106	97
Total Common Equity	137	106	97
Common Stock	1,391	1,431	1,492
Retained Earnings	-1,204	-1,277	-1,347
Accumulated Other Comprehensive Income / (Loss)	-50	-48	-48

This table presents Arbutus Biopharma's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q1 2023	Q2 2023	Q3 2023	Q1 2024	Q2 2024	Q3 2024
Total Assets	204	191	177	159	150	160	140
Total Current Assets	141	153	159	142	136	148	133
Cash & Equivalents	24	41	27	18	43	63	32
Short-Term Investments	111	106	125	117	86	79	96
Accounts Receivable	1.84	2.66	2.61	2.17	2.14	1.77	1.61
Prepaid Expenses	4.58	3.46	3.70	5.26	4.49	4.47	3.38
Plant, Property, & Equipment, net	5.24	4.85	5.37	5.03	4.41	4.06	3.56
Total Noncurrent Assets	57	34	13	12	10	7.76	4.11
Long-Term Investments	55	32	11	10	8.68	6.53	2.96
Other Noncurrent Operating Assets	1.99	1.73	1.60	1.51	1.33	1.24	1.14
Total Liabilities & Shareholders' Equity	204	191	177	159	150	160	140
Total Liabilities	58	47	42	39	36	38	34
Total Current Liabilities	28	25	25	22	20	23	19
Accounts Payable	12	9.65	8.81	9.81	8.25	11	7.54
Current Deferred Revenue	15	15	15	12	12	11	11
Other Current Liabilities	0.36	0.45	0.40	0.41	0.50	0.45	0.47
Total Noncurrent Liabilities	31	22	18	17	15	15	15
Other Noncurrent Operating Liabilities	20	19	18	17	15	15	15
Total Equity & Noncontrolling Interests	146	144	135	119	115	122	107
Total Preferred & Common Equity	146	144	135	119	115	122	107
Total Common Equity	146	144	135	119	115	122	107
Common Stock	1,378	1,414	1,421	1,426	1,458	1,485	1,489
Retained Earnings	-1,182	-1,220	-1,237	-1,257	-1,295	-1,314	-1,334
Accumulated Other Comprehensive Income / (Loss)	-51	-50	-49	-49	-48	-48	-48

This table displays calculated financial ratios and metrics derived from Arbutus Biopharma's official financial filings.

Metric	2022	2023	2024
Growth Metrics	-	-	-
Revenue Growth	255.11%	-53.51%	-65.98%
EBITDA Growth	9.41%	-23.03%	0.95%
EBIT Growth	10.93%	-19.24%	2.19%
NOPAT Growth	10.97%	-19.32%	2.28%
Net Income Growth	8.91%	-4.89%	4.02%
EPS Growth	44.58%	4.35%	13.64%
Operating Cash Flow Growth	47.65%	-143.06%	24.54%
Free Cash Flow Firm Growth	61.01%	-279.87%	28.21%
Invested Capital Growth	-119.90%	44.61%	3.85%
Revenue Q/Q Growth	8.45%	-18.43%	-8.47%
EBITDA Q/Q Growth	-3.83%	1.07%	8.30%
EBIT Q/Q Growth	-2.79%	1.51%	8.84%
NOPAT Q/Q Growth	-2.77%	2.27%	8.20%
Net Income Q/Q Growth	-0.89%	3.47%	8.84%
EPS Q/Q Growth	4.17%	2.22%	11.63%
Operating Cash Flow Q/Q Growth	6.89%	-0.35%	9.71%
Free Cash Flow Firm Q/Q Growth	8.19%	-0.78%	8.76%
Invested Capital Q/Q Growth	-6.24%	-3.67%	-5.82%
Profitability Metrics	-	-	-
Gross Margin	100.00%	100.00%	100.00%
EBITDA Margin	-164.29%	-434.76%	-1,265.97%
Operating Margin	-167.75%	-430.53%	-1,236.74%
EBIT Margin	-167.81%	-430.40%	-1,237.53%
Profit (Net Income) Margin	-178.01%	-401.57%	-1,133.04%
Tax Burden Percent	106.84%	100.00%	100.00%
Interest Burden Percent	99.29%	93.30%	91.56%
Effective Tax Rate	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	0.00%	0.00%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	0.00%	0.00%
Return on Net Nonoperating Assets (RNNOA)	0.00%	0.00%	0.00%
Return on Equity (ROE)	-45.35%	-59.99%	-68.76%
Cash Return on Invested Capital (CROIC)	0.00%	0.00%	0.00%
Operating Return on Assets (OROA)	-32.75%	-45.95%	-55.32%
Return on Assets (ROA)	-34.74%	-42.88%	-50.65%
Return on Common Equity (ROCE)	-45.35%	-59.99%	-68.76%
Return on Equity Simple (ROE_SIMPLE)	-50.75%	-68.71%	-71.81%
Net Operating Profit after Tax (NOPAT)	-46	-55	-53
NOPAT Margin	-117.43%	-301.37%	-865.72%
Net Nonoperating Expense Percent (NNEP)	-12.60%	-11.48%	-12.94%
Return On Investment Capital (ROIC_SIMPLE)	-	-51.57%	-54.87%
Cost of Revenue to Revenue	0.00%	0.00%	0.00%
SG&A Expenses to Revenue	45.71%	123.89%	358.26%
R&D to Revenue	216.33%	406.26%	875.66%
Operating Expenses to Revenue	267.75%	530.53%	1,336.74%
Earnings before Interest and Taxes (EBIT)	-65	-78	-76
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-64	-79	-78
Valuation Ratios	-	-	-
Price to Book Value (P/BV)	2.66	3.95	6.36
Price to Tangible Book Value (P/TBV)	2.66	3.95	6.36
Price to Revenue (P/Rev)	9.34	23.11	100.41
Price to Earnings (P/E)	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.00	0.00	0.00
Enterprise Value to Revenue (EV/Rev)	4.62	15.82	80.54
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00
Leverage & Solvency	-	-	-
Debt to Equity	0.00	0.00	0.00
Long-Term Debt to Equity	0.00	0.00	0.00
Financial Leverage	-1.23	-1.30	-1.25
Leverage Ratio	1.31	1.40	1.36
Compound Leverage Factor	1.30	1.31	1.24
Debt to Total Capital	0.00%	0.00%	0.00%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%
Common Equity to Total Capital	100.00%	100.00%	100.00%
Debt to EBITDA	0.00	0.00	0.00
Net Debt to EBITDA	0.00	0.00	0.00
Long-Term Debt to EBITDA	0.00	0.00	0.00
Debt to NOPAT	0.00	0.00	0.00
Net Debt to NOPAT	0.00	0.00	0.00
Long-Term Debt to NOPAT	0.00	0.00	0.00
Altman Z-Score	-5.07	-6.57	-4.34
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-
Current Ratio	4.60	5.87	8.15
Quick Ratio	4.51	5.68	8.01
Cash Flow Metrics	-	-	-
Free Cash Flow to Firm (FCFF)	-20	-76	-54
Operating Cash Flow to CapEx	-6,905.47%	-8,697.98%	-35,631.87%
Free Cash Flow to Firm to Interest Expense	-11.57	-165.20	-397.34
Operating Cash Flow to Interest Expense	-20.48	-187.22	-473.36
Operating Cash Flow Less CapEx to Interest Expense	-20.78	-189.38	-474.69
Efficiency Ratios	-	-	-
Asset Turnover	0.20	0.11	0.04
Accounts Receivable Turnover	34.67	11.60	2.95
Inventory Turnover	0.00	0.00	0.00
Fixed Asset Turnover	7.06	3.72	1.55
Accounts Payable Turnover	0.00	0.00	0.00
Days Sales Outstanding (DSO)	10.53	31.47	123.77
Days Inventory Outstanding (DIO)	0.00	0.00	0.00
Days Payable Outstanding (DPO)	0.00	0.00	0.00
Cash Conversion Cycle (CCC)	10.53	31.47	123.77
Capital & Investment Metrics	-	-	-
Invested Capital	-47	-26	-25
Invested Capital Turnover	-1.13	-0.49	-0.24
Increase / (Decrease) in Invested Capital	-26	21	1.01
Enterprise Value (EV)	180	287	497
Market Capitalization	365	419	620
Book Value per Share	$0.87	$0.63	$0.51
Tangible Book Value per Share	$0.87	$0.63	$0.51
Total Capital	137	106	97
Total Debt	0.00	0.00	0.00
Total Long-Term Debt	0.00	0.00	0.00
Net Debt	-184	-132	-123
Capital Expenditures (CapEx)	0.51	0.99	0.18
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-29	-16	-11
Debt-free Net Working Capital (DFNWC)	118	110	112
Net Working Capital (NWC)	118	110	112
Net Nonoperating Expense (NNE)	24	18	16
Net Nonoperating Obligations (NNO)	-184	-132	-123
Total Depreciation and Amortization (D&A)	1.37	-0.79	-1.76
Debt-free, Cash-free Net Working Capital to Revenue	-73.38%	-90.75%	-177.04%
Debt-free Net Working Capital to Revenue	303.14%	603.83%	1,810.05%
Net Working Capital to Revenue	303.14%	603.83%	1,810.05%
Earnings Adjustments	-	-	-
Adjusted Basic Earnings per Share	($0.46)	($0.44)	($0.38)
Adjusted Weighted Average Basic Shares Outstanding	150.94M	165.96M	185.61M
Adjusted Diluted Earnings per Share	($0.46)	($0.44)	($0.38)
Adjusted Weighted Average Diluted Shares Outstanding	150.94M	165.96M	185.61M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	162.57M	179.49M	191.48M
Normalized Net Operating Profit after Tax (NOPAT)	-44	-55	-49
Normalized NOPAT Margin	-113.42%	-301.11%	-793.74%
Pre Tax Income Margin	-166.62%	-401.57%	-1,133.04%
Debt Service Ratios	-	-	-
EBIT to Interest Expense	-37.94	-170.10	-557.43
NOPAT to Interest Expense	-26.55	-119.11	-389.95
EBIT Less CapEx to Interest Expense	-38.23	-172.26	-558.76
NOPAT Less CapEx to Interest Expense	-26.84	-121.26	-391.28
Payout Ratios	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%
Augmented Payout Ratio	15.80%	0.00%	0.00%

This table displays calculated financial ratios and metrics derived from Arbutus Biopharma's official financial filings.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Growth Metrics	-	-	-	-	-	-	-	-	-	-
Revenue Growth	78.20%	94.79%	-46.85%	-67.34%	-21.74%	-65.65%	-77.09%	-62.89%	-71.25%	-26.62%
EBITDA Growth	0.60%	-11.76%	-67.69%	-31.52%	-24.31%	3.80%	-12.11%	-22.13%	-1.10%	32.70%
EBIT Growth	3.21%	-8.54%	-58.64%	-25.82%	-20.86%	5.30%	-11.30%	-21.65%	0.54%	34.64%
NOPAT Growth	3.24%	-8.49%	-58.68%	-30.31%	-21.04%	8.04%	-11.20%	-17.39%	0.55%	32.84%
Net Income Growth	8.30%	-2.87%	-3.64%	-20.45%	-14.44%	11.95%	-9.40%	-15.81%	1.93%	35.11%
EPS Growth	50.00%	13.33%	9.09%	0.00%	0.00%	7.69%	0.00%	-10.00%	16.67%	41.67%
Operating Cash Flow Growth	-16.56%	13.34%	-232.41%	3.62%	-16.54%	-1.78%	29.32%	25.84%	4.81%	40.35%
Free Cash Flow Firm Growth	186.15%	170.42%	-210.11%	-283.58%	-431.54%	-454.49%	25.82%	43.24%	52.08%	69.83%
Invested Capital Growth	-104.79%	-119.90%	38.15%	39.28%	43.23%	44.61%	32.72%	9.67%	5.81%	3.85%
Revenue Q/Q Growth	-58.21%	4.92%	7.08%	-30.45%	0.15%	-53.95%	-28.58%	12.66%	-22.42%	17.55%
EBITDA Q/Q Growth	-28.81%	-27.96%	22.34%	-2.75%	-21.74%	0.97%	6.76%	-11.94%	-0.78%	34.08%
EBIT Q/Q Growth	-26.41%	-26.55%	22.85%	-1.95%	-21.43%	0.85%	6.55%	-11.43%	0.72%	34.84%
NOPAT Q/Q Growth	-26.24%	-26.67%	22.82%	-5.58%	-17.26%	3.76%	6.67%	-11.47%	0.66%	35.01%
Net Income Q/Q Growth	-23.78%	-24.85%	25.50%	-4.62%	-17.61%	3.94%	7.44%	-10.75%	0.40%	36.44%
EPS Q/Q Growth	-20.00%	-8.33%	23.08%	0.00%	-20.00%	0.00%	16.67%	-10.00%	9.09%	30.00%
Operating Cash Flow Q/Q Growth	7.89%	9.11%	-60.69%	28.36%	-11.38%	20.62%	-11.58%	24.83%	-42.97%	50.26%
Free Cash Flow Firm Q/Q Growth	-39.61%	-2.97%	-433.21%	5.99%	-9.07%	-3.75%	30.27%	28.06%	7.92%	34.67%
Invested Capital Q/Q Growth	6.04%	-6.24%	27.03%	16.63%	12.16%	-3.67%	11.38%	-11.94%	8.41%	-5.82%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-
Gross Margin	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
EBITDA Margin	-295.19%	-360.02%	-261.10%	-385.72%	-468.89%	-1,008.35%	-1,277.68%	-1,269.47%	-1,649.14%	-924.78%
Operating Margin	-299.24%	-361.28%	-260.40%	-395.29%	-462.82%	-967.23%	-1,263.90%	-1,250.46%	-1,601.19%	-885.20%
EBIT Margin	-299.60%	-361.35%	-260.34%	-381.60%	-462.69%	-996.22%	-1,264.75%	-1,250.93%	-1,600.82%	-887.29%
Profit (Net Income) Margin	-295.14%	-351.19%	-244.34%	-367.53%	-431.60%	-900.33%	-1,166.78%	-1,146.93%	-1,472.52%	-796.19%
Tax Burden Percent	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Interest Burden Percent	98.51%	97.19%	93.85%	96.32%	93.28%	90.37%	92.25%	91.69%	91.99%	89.73%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Net Nonoperating Assets (RNNOA)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Equity (ROE)	-49.95%	-45.35%	-45.22%	-50.68%	-56.99%	-59.99%	-57.54%	-59.96%	-67.81%	-68.76%
Cash Return on Invested Capital (CROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Return on Assets (OROA)	-58.36%	-70.51%	-40.29%	-45.74%	-56.79%	-106.37%	-96.18%	-74.72%	-72.17%	-39.66%
Return on Assets (ROA)	-57.50%	-68.53%	-37.81%	-44.06%	-52.97%	-96.13%	-88.73%	-68.51%	-66.39%	-35.59%
Return on Common Equity (ROCE)	-49.95%	-45.35%	-45.22%	-50.68%	-56.99%	-59.99%	-57.54%	-59.96%	-67.81%	-68.76%
Return on Equity Simple (ROE_SIMPLE)	-47.31%	0.00%	-48.66%	-54.15%	-63.24%	0.00%	-64.89%	-62.95%	-71.76%	0.00%
Net Operating Profit after Tax (NOPAT)	-12	-16	-12	-13	-15	-15	-14	-15	-15	-9.75
NOPAT Margin	-209.47%	-252.90%	-182.28%	-276.70%	-323.97%	-677.06%	-884.73%	-875.32%	-1,120.84%	-619.64%
Net Nonoperating Expense Percent (NNEP)	-2.98%	-3.27%	-2.07%	-2.32%	-2.99%	-3.03%	-2.73%	-3.00%	-3.42%	-2.18%
Return On Investment Capital (ROIC_SIMPLE)	-	-	-	-	-	-13.70%	-	-	-	-10.02%
Cost of Revenue to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
SG&A Expenses to Revenue	58.69%	68.04%	83.03%	128.57%	125.42%	237.81%	346.74%	437.25%	338.84%	299.36%
R&D to Revenue	336.95%	367.48%	273.29%	380.39%	433.00%	818.83%	1,005.42%	900.98%	1,065.94%	559.72%
Operating Expenses to Revenue	399.24%	461.28%	360.40%	508.97%	562.82%	1,037.58%	1,363.90%	1,350.46%	1,701.19%	985.20%
Earnings before Interest and Taxes (EBIT)	-18	-23	-17	-18	-22	-21	-19	-22	-21	-14
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-18	-22	-17	-18	-22	-22	-20	-22	-22	-15
Valuation Ratios	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	1.97	2.66	3.42	2.84	2.85	3.95	4.04	4.76	6.80	6.36
Price to Tangible Book Value (P/TBV)	1.97	2.66	3.42	2.84	2.85	3.95	4.04	4.76	6.80	6.36
Price to Revenue (P/Rev)	7.96	9.34	14.87	16.24	15.29	23.11	35.66	57.96	107.80	100.41
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Revenue (EV/Rev)	2.68	4.62	9.48	9.29	8.79	15.82	25.04	43.20	88.41	80.54
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Financial Leverage	-1.24	-1.23	-1.29	-1.27	-1.26	-1.30	-1.22	-1.21	-1.22	-1.25
Leverage Ratio	1.34	1.31	1.38	1.36	1.37	1.40	1.32	1.31	1.32	1.36
Compound Leverage Factor	1.32	1.27	1.30	1.31	1.28	1.26	1.22	1.20	1.22	1.22
Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Altman Z-Score	-4.61	-4.34	-2.01	-3.64	-5.31	-5.28	-3.68	-1.63	0.22	-2.77
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-
Current Ratio	5.13	4.60	6.08	6.47	6.34	5.87	6.69	6.56	7.02	8.15
Quick Ratio	4.96	4.51	5.94	6.32	6.11	5.68	6.47	6.36	6.84	8.01
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	10	10	-34	-32	-34	-36	-25	-18	-16	-11
Operating Cash Flow to CapEx	-20,540.66%	-11,032.47%	-23,334.19%	-2,276.95%	-68,075.00%	0.00%	-20,310.53%	-1,450,400.00%	0.00%	-11,994.19%
Free Cash Flow to Firm to Interest Expense	24.18	32.57	-169.37	-184.38	-747.58	-810.86	-565.39	-526.39	-568.24	-358.84
Operating Cash Flow to Interest Expense	-43.57	-54.98	-137.88	-114.38	-473.57	-393.00	-438.52	-426.59	-715.03	-343.83
Operating Cash Flow Less CapEx to Interest Expense	-43.78	-55.48	-138.47	-119.40	-474.26	-393.00	-440.68	-426.62	-715.03	-346.70
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.19	0.20	0.15	0.12	0.12	0.11	0.08	0.06	0.05	0.04
Accounts Receivable Turnover	20.55	34.67	16.66	10.27	11.10	11.60	5.41	4.59	3.57	2.95
Inventory Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Fixed Asset Turnover	6.21	7.06	6.30	4.33	4.33	3.72	2.80	2.13	1.57	1.55
Accounts Payable Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Sales Outstanding (DSO)	17.76	10.53	21.91	35.55	32.87	31.47	67.50	79.47	102.29	123.77
Days Inventory Outstanding (DIO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Payable Outstanding (DPO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Cash Conversion Cycle (CCC)	17.76	10.53	21.91	35.55	32.87	31.47	67.50	79.47	102.29	123.77
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-
Invested Capital	-45	-47	-35	-29	-25	-26	-23	-26	-24	-25
Invested Capital Turnover	-1.08	-1.13	-0.73	-0.62	-0.64	-0.49	-0.45	-0.37	-0.27	-0.24
Increase / (Decrease) in Invested Capital	-23	-26	21	19	19	21	11	2.79	1.47	1.01
Enterprise Value (EV)	96	180	314	219	195	287	325	435	596	497
Market Capitalization	286	365	493	382	340	419	463	583	727	620
Book Value per Share	$0.97	$0.87	$0.89	$0.81	$0.71	$0.63	$0.64	$0.65	$0.57	$0.51
Tangible Book Value per Share	$0.97	$0.87	$0.89	$0.81	$0.71	$0.63	$0.64	$0.65	$0.57	$0.51
Total Capital	146	137	144	135	119	106	115	122	107	97
Total Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Long-Term Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt	-190	-184	-179	-164	-145	-132	-138	-149	-131	-123
Capital Expenditures (CapEx)	0.09	0.15	0.12	0.86	0.03	0.00	0.10	0.00	0.00	0.09
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-21	-29	-19	-18	-15	-16	-14	-16	-14	-11
Debt-free Net Working Capital (DFNWC)	114	118	128	134	119	110	116	126	114	112
Net Working Capital (NWC)	114	118	128	134	119	110	116	126	114	112
Net Nonoperating Expense (NNE)	5.10	6.14	4.15	4.22	5.01	4.79	4.32	4.69	4.71	2.78
Net Nonoperating Obligations (NNO)	-190	-184	-179	-164	-145	-132	-138	-149	-131	-123
Total Depreciation and Amortization (D&A)	0.26	0.08	-0.05	-0.19	-0.29	-0.26	-0.20	-0.32	-0.65	-0.59
Debt-free, Cash-free Net Working Capital to Revenue	-58.61%	-73.38%	-57.44%	-77.39%	-66.98%	-90.75%	-105.22%	-162.62%	-206.76%	-177.04%
Debt-free Net Working Capital to Revenue	315.81%	303.14%	385.51%	570.52%	536.32%	603.83%	890.00%	1,248.63%	1,688.73%	1,810.05%
Net Working Capital to Revenue	315.81%	303.14%	385.51%	570.52%	536.32%	603.83%	890.00%	1,248.63%	1,688.73%	1,810.05%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($0.12)	($0.13)	($0.10)	($0.10)	($0.12)	($0.12)	($0.10)	($0.11)	($0.10)	($0.07)
Adjusted Weighted Average Basic Shares Outstanding	151.00M	150.94M	161.64M	166.06M	167.51M	165.96M	175.63M	188.04M	189.00M	185.61M
Adjusted Diluted Earnings per Share	($0.12)	($0.13)	($0.10)	($0.10)	($0.12)	($0.12)	($0.10)	($0.11)	($0.10)	($0.07)
Adjusted Weighted Average Diluted Shares Outstanding	151.00M	150.94M	161.64M	166.06M	167.51M	165.96M	175.63M	188.04M	189.00M	185.61M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	156.47M	162.57M	166.13M	167.56M	167.70M	179.49M	188.72M	188.78M	189.49M	191.48M
Normalized Net Operating Profit after Tax (NOPAT)	-12	-16	-12	-13	-15	-15	-14	-15	-12	-9.75
Normalized NOPAT Margin	-209.47%	-252.90%	-182.28%	-276.70%	-323.97%	-677.06%	-884.73%	-875.32%	-931.33%	-619.64%
Pre Tax Income Margin	-295.14%	-351.19%	-244.34%	-367.53%	-431.60%	-900.33%	-1,166.78%	-1,146.93%	-1,472.52%	-796.19%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	-41.57	-73.03	-87.92	-103.79	-468.52	-485.66	-440.36	-635.03	-739.14	-465.53
NOPAT to Interest Expense	-29.06	-51.11	-61.56	-75.26	-328.06	-330.07	-308.05	-444.36	-517.52	-325.10
EBIT Less CapEx to Interest Expense	-41.78	-73.53	-88.52	-108.81	-469.22	-485.66	-442.52	-635.06	-739.14	-468.40
NOPAT Less CapEx to Interest Expense	-29.27	-51.61	-62.15	-80.28	-328.75	-330.07	-310.21	-444.39	-517.52	-327.97
Payout Ratios	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	15.80%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Frequently Asked Questions About Arbutus Biopharma's Financials

When does Arbutus Biopharma's financial year end?

According to the most recent income statement we have on file, Arbutus Biopharma's fiscal year ends in December. Their fiscal year 2024 ended on December 31, 2024.

How has Arbutus Biopharma's net income changed over the last 2 years?

The last 5 years of Arbutus Biopharma's net income performance:

2022: -$69.46 million
2023: -$72.85 million
2024: -$69.92 million

What is Arbutus Biopharma's operating income?

Arbutus Biopharma's total operating income in 2024 was -$76.32 million, based on the following breakdown:

Total Gross Profit: $6.17 million
Total Operating Expenses: $82.49 million

How has Arbutus Biopharma revenue changed over the last 2 years?

Over the last 2 years, Arbutus Biopharma's total revenue changed from $39.02 million in 2022 to $6.17 million in 2024, a change of -84.2%.

How much debt does Arbutus Biopharma have?

Arbutus Biopharma's total liabilities were at $34.34 million at the end of 2024, a 10.5% decrease from 2023, and a 41.4% decrease since 2022.

How much cash does Arbutus Biopharma have?

In the past 2 years, Arbutus Biopharma's cash and equivalents has ranged from $26.29 million in 2023 to $36.33 million in 2024, and is currently $36.33 million as of their latest financial filing in 2024.

How has Arbutus Biopharma's book value per share changed over the last 2 years?

Over the last 2 years, Arbutus Biopharma's book value per share changed from 0.87 in 2022 to 0.51 in 2024, a change of -41.3%.

Related Companies

This page (NASDAQ:ABUS) was last updated on 4/25/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Arbutus Biopharma (ABUS) Financials

Frequently Asked Questions About Arbutus Biopharma's Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Arbutus Biopharma (ABUS) Financials

Annual Income Statements for Arbutus Biopharma

Quarterly Income Statements for Arbutus Biopharma

Annual Cash Flow Statements for Arbutus Biopharma

Quarterly Cash Flow Statements for Arbutus Biopharma

Annual Balance Sheets for Arbutus Biopharma

Quarterly Balance Sheets for Arbutus Biopharma

Annual Metrics and Ratios for Arbutus Biopharma

Quarterly Metrics and Ratios for Arbutus Biopharma

Frequently Asked Questions About Arbutus Biopharma's Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools